Chimera Therapeutics (KYMR), "Oral Immunotherapy" Anticipation Explodes… STAT6 Reduced by 98%

Chimera Therapeutics (KYMR) has announced early clinical trial results for its next-generation oral “STAT6 degrader” immunological disease treatment drug KT-621, raising market expectations. With mid-stage clinical trials for atopic dermatitis and asthma yielding visible results, some evaluations suggest that the competitive landscape for “oral immunotherapy drugs” capable of replacing biological agents has officially begun.

On the 28th (local time), Chimera Therapeutics (KYMR) presented data from the phase 1b “BroADen” clinical trial of KT-621 at the American Academy of Dermatology (AAD) 2026 meeting. Results from a 28-day dosing regimen involving 22 patients with moderate to severe atopic dermatitis showed that STAT6 protein levels in the blood decreased by as much as 98%. Given the significant target degradation effect achieved by this mechanism drug in real human subjects, this is a noteworthy outcome.

Significant improvements were also observed in clinical indicators. The company stated that a clear downward trend was confirmed in both clinical symptom indicators and inflammation-related biomarkers, which is interpreted as surpassing mere biochemical responses and suggesting the potential for actual treatment. Industry experts believe that, given the STAT6 pathway is the core axis of allergic and inflammatory responses, these results may serve as a starting point for changes in future treatment paradigms.

Currently, Chimera Therapeutics (KYMR) is simultaneously advancing the “BROADEN2” phase 2b trial for atopic dermatitis and the “BREADTH” phase 2b trial for asthma. Clinical trial results for atopic dermatitis are expected to be announced in mid-2027, while asthma data is projected for the second half of 2027. Notably, both indications have already formed large-scale markets, so their success or failure is expected to have substantial commercial impact.

The company also emphasized that KT-621 has previously received “Fast Track” designation from the U.S. Food and Drug Administration (FDA). This is a factor that could accelerate the development and review process, potentially having a positive impact on future clinical trial timelines and market entry timing.

The financial foundation is also relatively solid. Chimera has stated that it has secured approximately $1.6 billion (about 2.304 trillion KRW) in cash, sufficient to sustain operations until 2029. Additionally, the company successfully completed a public offering of approximately $692.3 million (about 996.6 billion KRW) in 2025, further ensuring additional capital reserves.

The market is watching whether Chimera Therapeutics (KYMR) can transcend being merely a new drug development company and position itself as a “protein degradation” platform enterprise. CEO Nello Mainolfi stated, “We will bring transformation to the existing injection-centered market through oral immunological disease treatment drugs.” Its follow-up pipeline IRF5 degrader KT-579 is also planned to enter clinical trials in 2026.

Commentary: The early clinical data for KT-621 shows quite strong signals in terms of efficacy, but its actual commercial success will depend on the extent to which reproducibility and safety can be assured in the phase 2b trials. In particular, the convenience of administration compared to existing biological agents is very clear, leading to evaluations suggesting it has sufficient potential to shake up the competitive landscape in the medium to long term.